公 司 研 究 [Table_Reportdate] 2024年08月12日 医 药 生 物 安杰思 沪深300 [Table_invest] 买入（维持） 报告原因：业绩点评 able_Authors] 证券分析师 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn | --- | --- | |---------------------------|--------------| | | | | 数据日期 Table_cominfo] | 2024/08/09 | | 收盘价 | 53.81 | | 总股本 ( 万股 ) | 8,086 | | 流通 A 股 /B 股 ( 万股 ) | 4,063/0 | | 资产负债率 (%) | 4.16% | | 市净率 ( 倍 ) | 1.96 | | 净资产收益率 ( 加权 ) | 5.51 | | 12 个月内最高 / 最低价 | 128.47/47.01 | [Table_QuotePic] -48% -36% -24% -12% 0% 12% 2 ...

公 司 半 年 报 点 评 证 券 研 究 报 告 公 司 报 告 | --- | --- | --- | |------------------------|-------|----------------------------------| | 行业 | | 医药 | | 公司网址 | | www.bioags.com | | 大股东 / 持股 | | 杭州一嘉投资管理有限公司 /32.71% | | 实际控制人 | | 张承 | | 总股本 ( 百万股 ) | | 81 | | 流通 A 股 ( 百万股 ) | | 41 | | 流通 B/H 股 ( 百万股 ) | | | | 总市值 ( 亿元 ) | | 43 | | 流通 A 股市值 ( 亿元 ) | | 22 | | 每股净资产 ( 元 ) | | 27.47 | | 资产负债率 (%) | | 4.2 | | 行情走势图 | | | | | | | 安杰思(688581.SH) 国内外双轮驱动增长，利润端表现亮眼 股价:53.36元 请通过合法途径获取本公司研究报告，如经由未经许可的渠道获得研究报告，请慎重使用并注意阅读研究报告尾页的声明内容 ...

安杰思（688581.SH） 24 年半年报业绩点评：业绩超预期，海内外双轮 驱动，盈利能力持续提升 投资要点： 公司发布 2024 年半年报。 2024 年上半年公司实现营收 2.64 亿（同比+28.4%），归母净利润 1.24 亿元（同比+57.9%），扣非归母净利润 1.20 亿元（同比+56.3%）。 2024Q2 公司实现营收 1.52 亿元（同比+32.4%），归母净利润 7167 万元（同比+60.8%），扣非归母净利润 7170 万元（同比+68.3%）。 核心品类收入高增，毛利率持续上行。 24H1 公司积极开拓市场，GI 类、ESD/EMR 类核心产品销售快速 增长，带动毛利率提升，实现主营毛利率 71.7%（较上年同期提升 2.88pct）。其中 1）GI 类产品收入 1.71 亿元（同比+29.2%），毛利率 提升 1.66pct；2）ESD/EMR 类收入 6306 万元（同比+55.8%），毛利 率提升 7.05pct；3）ERCP 类收入 2025 万元（同比+14.3%）。 海内外双轮驱动，海外营收增速超预期。 24H1 国内实现营收 1.25 亿元（同比+22%），新增临床 ...

幅证券 医药生物/医疗器械 司研究 安杰思 (688581.SH) 2024 年 08 月 09 日 2024H1 业绩超预期，国内外市场拓围驱动成长 公司信息更新报告 投资评级：买入（维持） | --- | --- | |-------------------|--------------| | 日 期 | 2024/8/8 | | 当前股价(元) | 53.36 | | 一年最高最低(元) | 128.47/47.01 | | 总市值(亿元) | 43.15 | | 流通市值(亿元) | 21.68 | | 总股本(亿股) | 0.81 | | 流通股本(亿股) | 0.41 | | 近３个月换手率(%) | 86.34 | 股价走势图 沪深300 安然思 48% 32% 16% ()% -16% -32% -48% 2024-08 2023-08 2023-12 2024-04 数据来源：聚源 相关研究报告 《内镜诊疗器械领军企业，国内外市 场拓園+产品送代驱动成长—公司首 次覆盖报告》-2024.7.23 | --- | --- | |--------------------------|------ ...

幅证券 医药生物/医疗器械 公 司 研 究 安杰思（688581.SH） 2024 年 08 月 09 日 2024H1 业绩超预期，国内外市场拓围驱动成长 ——公司信息更新报告 投资评级：买入（维持） | --- | --- | |-------------------------|--------------| | 日期 | 2024/8/8 | | 当前股价 ( 元 ) | 53.36 | | 一年最高最低 ( 元 ) | 128.47/47.01 | | 总市值 ( 亿元 ) | 43.15 | | 流通市值 ( 亿元 ) | 21.68 | | 总股本 ( 亿股 ) | 0.81 | | 流通股本 ( 亿股 ) | 0.41 | | 近 3 个月换手率 (%) | 86.34 | 股价走势图 -48% -32% -16% 0% 16% 32% 48% 2023-08 2023-12 2024-04 2024-08 安杰思 沪深300 数据来源：聚源 相关研究报告 《内镜诊疗器械领军企业，国内外市 场拓围+产品迭代驱动成长—公司首 次覆盖报告》-2024.7.23 | --- | --- | |--- ...

杭州安杰思医学科技股份有限公司 关于向 2023 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688581 证券简称：安杰思 公告编号：2024-035 《杭州安杰思医学科技股份有限公司2023年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"或"本激励计划"）规定的限制性股票预 留授予条件已经成就，根据杭州安杰思医学科技股份有限公司（以下简称"本公 司"或"公司"）已获2023年第二次临时股东大会授权，公司于2024年8月7日召 开第二届董事会第十五次会议、第二届监事会第十一次会议，审议通过了《关于 向激励对象授予预留限制性股票的议案》，同意以2024年8月7日为本激励计划的 预留授予日，并以48.96元/股的授予价格向18名符合条件的激励对象预留授予共 计119,000股限制性股票。关于授予价格和授予数量调整的具体内容详见公司同 日在上海证券交易所网站（www.sse.com.cn）披露的《关于调整公司2023年限 ...

杭州安杰思医学科技股份有限公司 关于公司 2024 年度提质增效重回报专项行动方案的半年度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，践行"以投资者为本" 的上市公司发展理念，推动杭州安杰思医学科技股份有限公司（以下简称"公 司"）持续优化经营、规范治理和积极回报投资者，大力提高公司质量，助力 信心提振、资本市场稳定和经济高质量发展，基于对公司未来发展前景的信心、 对公司价值的认可和切实履行社会责任,公司于 2024 年 4 月 23 日发布了《2024 年度"提质增效重回报"专项行动方案》，通过持续加强自身价值创造能力， 切实履行上市公司的责任和义务，回报投资者信任，维护公司在资本市场形象， 共同促进资本市场平稳健康发展。现将行动方案进展半年度评估情况报告如下： 一、夯实企业内部实力，助力企业优质发展 1、 继续建立丰富的技术储备，夯实公司研发能力 上半年公司研发投入合计 2585.19 万元，占同期营业收入比例为 9.79%，较 去年同期增加 1.03 个百分点。上半年公司各研发项目进展顺利，其中在售品设 计改善项期初 25 项，上半年新增 8 项完结 6 项，在售品设计改善进行中项目 27 ...

杭州安杰思医学科技股份有限公司 章 程 二〇二四年八月 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 11 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 16 | | 第五节 | 股东大会的召开 18 | | 第六节 | 股东大会的表决和决议 21 | | 第五章 | 董事会 26 | | 第一节 | 董事 26 | | 第二节 | 董事会 31 | | 第六章 | 总经理及其他高级管理人员 37 | | 第七章 | 监事会 39 | | 第一节 | 监事 39 | | 第二节 | 监事会 40 | | 第八章 | 财务会计制度、利润分配和审计 42 | | 第一节 | 财务会计制度 42 | | 第二节 | 内部审计 46 | | 第三节 | 会计师事务所的聘任 46 ...

杭州安杰思医学科技股份有限公司 2023 年限制性股票激励计划预留授予激励对象名单 （截至预留授予日） | 姓名 | 国籍 | 职务 | 获授的限制性股票 数量（股） | 占预留授予限制性 股票总数的比例 | 占公司总股本的 比例 | | --- | --- | --- | --- | --- | --- | | 1.董事、高级管理人员 | | | | | | | 韩春琦 | 中国 | 董事、副总经 理 | 1960 | 1.65% | 0.0024% | | 2.其他激励对象 | | | | | | | 中层管理人员及核心技术（业务）骨 | | | 117040 | 98.35% | 0.1447% | | 人） | 干（17 | | | | | | 合计 | | | 119,000 | 100.000% | 0.15% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票数量累计 未超过本次激励计划草案公告时公司股本总额的 1.00%。公司全部在有效期内的股权激励计划所涉 及的标的股票总额累计未超过本次激励计划草案公告时公司股本总额的 20.00%。 2、本次激励计划预留授予激 ...

Financial Performance - The company achieved a revenue of RMB 1.23 billion in the first half of 2024, representing a year-on-year growth of 15.6%[1] - The gross profit margin for the period was 65.8%, an increase of 2.3 percentage points compared to the same period last year[1] - The company's net profit reached RMB 320 million, up by 18.4% year-on-year[1] - Revenue increased by 28.43% year-on-year to RMB 264 million, driven by strong growth in the Chinese and US markets, particularly in GI and ESD/EMR product categories[14] - Net profit attributable to shareholders rose by 57.93% to RMB 124.45 million, supported by increased sales, improved gross margins, and higher interest income[14] - Operating cash flow surged by 65.64% to RMB 116.27 million, reflecting higher cash inflows from sales[14] - Basic earnings per share (EPS) grew by 25.57% to RMB 1.5428, reflecting improved profitability[17] - Weighted average return on equity (ROE) decreased by 5.81 percentage points to 5.51%, primarily due to changes in equity structure[17] - Total revenue for the first half of 2024 reached 264,000,678.80 RMB, a 28.4% increase compared to 205,558,880.81 RMB in the same period of 2023[129] - Net profit attributable to the parent company increased to 437,635,027.29 RMB in the first half of 2024, up 6.1% from 412,335,342.45 RMB in the same period of 2023[128] - Net profit reached 124,453,227.74, a 58% increase year-over-year[130] - Operating profit grew to 145,089,365.64, up 61.7% compared to the same period last year[130] - Revenue from the parent company rose to 263,515,540.68, up 28.3% compared to the previous year[132] - Comprehensive income for the first half of 2024 reached 131,618,394.69 RMB, an increase from 79,266,307.59 RMB in the same period last year[135] R&D and Innovation - The R&D investment in the first half of 2024 was RMB 150 million, accounting for 12.2% of the total revenue[1] - R&D investment as a percentage of revenue increased by 1.03 percentage points to 9.79%, indicating a stronger focus on innovation[17] - The company's core technologies include bipolar circuit technology, clip-assisted tissue traction technology, reloadable technology, and continuous firing technology, with 11, 1, 11, and 1 patents granted respectively, and additional patents pending[28] - The company has developed fiber optic imaging (multimodal imaging technology) capable of high-resolution imaging on a 1mm diameter cross-section, with 6 patents pending[30] - The company is developing an endoscopic surgical assist robot, which is set to enter animal testing, with 7 patents pending[31] - The company has made progress in flexible endoscopes, solving operational issues and mastering core algorithms for light source selection and image processing, with 14 patents pending[32] - In the reporting period, the company applied for 39 new invention patents, 6 new utility model patents, and 5 new design patents, with a cumulative total of 54 invention patents, 39 utility model patents, and 4 design rights granted[33] - Total R&D investment increased by 43.60% to 25,851,895.22 yuan, with R&D investment accounting for 9.79% of total revenue, an increase of 1.03 percentage points[39] - R&D investment increased significantly due to higher spending on soft endoscopes and auxiliary therapeutic robots, as well as an increase in R&D personnel[40] - The number of R&D personnel increased to 127, accounting for 18.9% of the total workforce, up from 98 and 17.22% in the previous year[44] - R&D personnel's average salary increased to 11.43 from 10.81 in the previous year[44] Market Expansion and Sales - The company's overseas revenue grew by 25.3% year-on-year, reaching RMB 480 million[1] - The company completed the acquisition of a European medical device manufacturer for EUR 50 million, expanding its market presence in Europe[1] - The company's sales model includes distribution and ODM, with domestic sales primarily through distribution and overseas sales through ODM and distribution, expanding its own brand sales overseas[27] - The company successfully registered 32 new products in international markets, including Saudi Arabia, Thailand, and Paraguay[35][36] - The company expanded its product portfolio in Malaysia and Turkey by adding new specifications and series to existing products[38] - Asia-Pacific region sales revenue grew by 82.86%, North America by 68.49%, and South America by 53.74% year-over-year[50][51] - Overseas sales revenue increased by 35.28% year-on-year, with Asia-Pacific region growing by 82.86%, North America by 68.49%, and South America by 53.74%. Own-brand sales accounted for nearly 30%[55] - The Dutch subsidiary will commence physical operations in the second half of the year to expand the international marketing network[55] - The company added 14 new cooperative clients and participated in academic conferences such as DDW and ESGE DAYS[55] - The company expanded its hospital network by adding 198 new hospitals and 400 effective channels, with products covering 31 provinces, autonomous regions, and municipalities[54] - The company participated in over 60 academic conferences, including the 21st Wuhan Union Digestive Disease Conference and the 21st Beijing International Digestive Disease Forum, enhancing market penetration[54] Production and Operations - The company's new production facility in Hangzhou is expected to be operational by the end of 2024, with an annual production capacity of 50,000 units[1] - The company's production model includes domestic inventory and overseas order-based production, ensuring efficient production through collaboration between marketing, production, and quality departments[25] - Production output increased by over 30% year-over-year due to the application of lean production concepts and the use of new factory facilities[49] - The company's procurement model emphasizes quality, cost, and timely delivery, with a focus on establishing a supply chain and supplier management system that meets operational needs[26] - The company has achieved automated assembly for multiple processes of products like electrosurgical snares, biopsy forceps, and clip devices[57] - The company has obtained ISO 13485:2016 certification and market access qualifications in multiple countries including the US, EU, Japan, Canada, Brazil, Australia, UK, Switzerland, and South Korea[55] Financial Position and Cash Flow - The company's cash and cash equivalents stood at RMB 1.8 billion as of June 30, 2024, providing strong financial flexibility for future investments[1] - Operating cash flow surged by 65.64% to RMB 116.27 million, reflecting higher cash inflows from sales[14] - The company's cash and cash equivalents decreased from 1,954,739,150.26 as of December 31, 2023, to 964,766,200.12 as of June 30, 2024[123] - Net cash flow from operating activities for the first half of 2024 was 116,273,846.99 RMB, compared to 70,197,212.78 RMB in the same period last year[136] - Net cash flow from investing activities for the first half of 2024 was -992,813,720.80 RMB, a significant decrease from 31,145,027.33 RMB in 2023[136] - Net cash flow from financing activities for the first half of 2024 was -114,361,075.58 RMB, compared to 1,647,493,638.86 RMB in the same period last year[136] - The company's cash and cash equivalents at the end of the first half of 2024 were 964,759,200.12 RMB, down from 1,960,785,293.76 RMB at the end of 2023[137] - Cash received from other investment activities in the first half of 2024 was 449,985,159.85 RMB, a significant increase from 56,601,493.74 RMB in 2023[136] - Cash paid for other investment activities in the first half of 2024 was 1,417,427,542.27 RMB, compared to no significant amount in 2023[136] - Cash received from financing activities in the first half of 2024 was 1,820,326,000.00 RMB, compared to no significant amount in 2023[136] - The net increase in cash and cash equivalents for the first half of 2024 was -989,972,950.14 RMB, a significant decrease from 1,748,925,812.72 RMB in 2023[137] Market and Industry Trends - The global medical device market size reached $440 billion in 2020 and is expected to exceed $800 billion by 2030, with a CAGR of 6.3% from 2020 to 2030[23] - China's medical device market size grew from RMB 312.6 billion in 2015 to RMB 778.9 billion in 2020, with a CAGR of 20%, and is expected to exceed RMB 2.2 trillion by 2030, with a CAGR of 11% from 2020 to 2030[23] - The domestic gastrointestinal endoscopy diagnostic and therapeutic device market size is expected to grow from RMB 3.73 billion in 2019 to RMB 11.42 billion by 2030[24] - The global endoscopy diagnostic and therapeutic device market size is expected to grow from $5 billion in 2021 to $6 billion by 2024, with a CAGR of 6%[24] - Imported brands accounted for 93.1% of China's medical endoscope market in 2021, but domestic brands are expected to increase their market share to 18.3% by 2025 and 35.2% by 2030[24] - The company operates in the medical device manufacturing industry (C358) under the specialized equipment manufacturing sector (C35)[21] - The Chinese government has implemented policies to support innovation in medical devices, including optimizing approval processes, strengthening intellectual property protection, and promoting domestic equipment innovation[21] - The volume-based procurement policy for medical devices has promoted market competition, reduced procurement costs, and improved supply chain efficiency[21] - The DRG/DIP payment reform has encouraged medical institutions to actively control costs and standardize medical practices[21] - The company focuses on the research, production, and sales of minimally invasive endoscopic diagnostic and therapeutic devices, with a growing emphasis on technological innovation and domestic market expansion[21] - The domestic production rate of minimally invasive surgical consumables is expected to further increase, with domestic manufacturers gradually breaking through in mid-to-high-end products and potentially gaining more global market share[25] Intellectual Property and Patents - The company obtained 334 intellectual property rights, including 17 design patents and 7 software copyrights[34] - The company submitted 334 patent applications, with 97 authorized patents, including 54 invention patents, and 55% of patents applied in related products[53] - The company launched innovative products such as the reloadable hemostatic clip, which reduces clinical costs, and the coated guidewire for ERCP, which improves cannulation success rates[53] Risks and Challenges - The company faces intensified competition in both domestic and international markets for minimally invasive endoscopic devices[59] - The company has established a comprehensive quality system to prevent product performance defects and enhance brand influence[59] - The company's products, including biliary drainage tubes and high-frequency cutting knives, have been included in centralized procurement programs in multiple provinces, potentially impacting sales prices and profit margins[61] - The company faces risks from international trade friction and exchange rate fluctuations, as its primary export markets are in the EU and North America, with transactions primarily settled in USD[60] - Medical device industry policy changes, particularly the centralized procurement reform, may impact the company's operations and profitability[60] - The company is actively monitoring macroeconomic conditions and adjusting its business strategies to mitigate potential risks[61] - Intellectual property risks exist, particularly regarding the "AGS" trademark in the domestic market, which could affect product promotion and sales[61] - The company is implementing measures to retain technical talent and maintain its competitive advantage in innovation[63] Corporate Governance and Shareholder Commitments - The actual controller Zhang Cheng and related parties have committed to a 36-month lock-up period for their shares post-IPO, with specific conditions for extending the lock-up period if the stock price falls below the issue price for 20 consecutive trading days within 6 months of listing[85] - Zhang Cheng's immediate family members, Zhang Qianyi and Zhang Beijia, have also committed to a 36-month lock-up period for their indirectly held shares, with similar conditions for extending the lock-up period[86] - Major shareholders including Hangzhou Yijia, Ningbo Jiayi, and Ningbo Dingjie have committed to a 36-month lock-up period for their shares, with conditions for extending the lock-up period if the stock price falls below the issue price for 20 consecutive trading days within 6 months of listing[87] - The company has established a long-term effective dividend policy, as indicated in the 2024 semi-annual report[83] - The company has resolved issues related to competition with entities controlled by the actual controller, Zhang Cheng, and related parties[84] - The company has implemented a restricted stock incentive plan for 2023, with a 36-month lock-up period post-grant[84] - The company has made various commitments related to its IPO, including those from directors, supervisors, and senior management, which are long-term effective[84] - The company has established a long-term effective policy for handling other commitments, including those related to the IPO and equity incentives[84] - The company has made commitments related to the lock-up of shares held by its major shareholders and actual controller, with specific conditions for extending the lock-up period[88] - The company has established a long-term effective policy for handling other commitments, including those related to the IPO and equity incentives[88] - Shareholders holding more than 5% of the company's shares, including Da'an Gene, Guangzhou Da'an, Suzhou New Construction, and Tianfu Silicon Valley Zhenghui, have committed to a 12-month lock-up period post-listing, during which they will not transfer or entrust others to manage their shares[89] - Ningbo Daohe has also committed to a 12-month lock-up period post-listing, with similar restrictions on share transfers and management[90] - Directors, supervisors, and senior management indirectly holding shares through Ningbo Dingjie are subject to a 12-month lock-up period, with annual transfer limits of 25% of their holdings during their tenure[91] - Core technical personnel indirectly holding shares through Ningbo Dingjie are subject to a 12-month lock-up period, with annual transfer limits of 25% of their holdings for 4 years post-lock-up[92] - Actual controller Zhang Cheng has committed to adhering to IPO share lock-up and transfer restrictions, with specific rules for share reduction through various trading methods[93] - Controlling shareholder Hangzhou Yijia and related entities have committed to adhering to IPO share lock-up and transfer restrictions, with specific rules for share reduction through various trading methods[93] - The company's major shareholders, including Da'an Gene, Guangzhou Da'an, Suzhou New Yuan, and Silicon Valley Zhenghui, hold more than 5% of the company's shares and have committed to comply with IPO share lock-up and reduction rules[94] - If the company's stock price falls below the net asset value per share for 20 consecutive trading days within three years of listing, the company will initiate a stock price stabilization plan[95] - The company's controlling shareholder or its controlled entities will increase their shareholding by at least RMB 5 million within three months if the stock price stabilization plan is triggered, with the total number of shares not exceeding 2% of the company's total shares before the increase[96] - If the controlling shareholder fails to implement the share increase plan, the company may withhold cash dividends payable to the controlling shareholder until the cumulative amount reaches RMB 5 million[96] - If the stock price remains below the net asset value after the controlling shareholder's share increase, the company's directors (excluding independent directors) and senior management will increase their shareholding by at least 30% of their after-tax salary from the previous year within three months[96] - If the stock price remains below the net asset value after the directors' and senior management's share increase, the company will initiate a stock repurchase plan of at least RMB 10 million within three months, with the total number of shares not exceeding 2% of the company's total shares before the repurchase[96] - Any amendments to the stock price stabilization plan must be approved by at least two-thirds of the voting rights at the company's shareholders' meeting[96] - The company, its controlling shareholder, directors, and senior management must fulfill their obligations under the stock price stabilization plan in accordance with relevant regulations and disclose information accordingly[96] - The company's actual controller and related parties have extended the lock-up period for their pre-IPO shares by 6 months due to the stock price falling below the issue price for 20 consecutive trading days[100] - The company has committed to not providing loans or any form of financial assistance to incentive recipients for acquiring restricted shares under the incentive plan[99] - The company has outlined measures to prevent the dilution of immediate returns, including commitments from controlling shareholders, actual controllers, directors, and senior management[97] - The company's profit distribution policy prioritizes cash dividends and requires specific conditions to be met for cash dividends, such as positive undistributed profits and profitability[97] - The company has committed to avoiding conflicts of interest and ensuring that no illegal shareholding or improper benefits transfer occurs[98] Environmental and Social Responsibility - Environmental protection investment during the reporting period amounted to 3.46 million yuan[78] - Wastewater treatment includes industrial wastewater from metal part polishing and cleaning, and domestic sewage discharged into municipal sewage networks[78] - Waste gas from sterilization is treated using EO tail gas adsorption equipment before emission[78] - Solid waste from production is collected and processed by qualified units[78] - No carbon reduction measures or CO2 equivalent reductions were reported during the period[79] - No equity incentives, employee stock ownership plans, or other employee incentive measures were implemented or changed during the reporting period[77] - The company is not classified as a key pollutant discharge unit and has no significant pollution-related penalties[78] Legal and Regulatory Compliance - The company has disclosed that there are no significant lawsuits or arbitration cases during the